A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY)

A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY)

Objective: To compare the antitumor efficacy, safety, and pharmacodynamic (PD) characteristics of Hetero-rituximab (test) with reference medicinal product (rituximab, Roche) in non-Hodgkin's lymphoma. Patients and Methods: One hundred and thirty-five patients with diffuse large B-cell lymphoma...

Full description

Saved in:
Bibliographic Details
Main Authors: Suresh Advani, Ghanashyam Biswas, Shubhadeep Sinha, Neetu Naidu Rayala, Sreenivasa Chary, Pankaj Thakur, Anushrita, Santanu Tripathi, Vamsi Krishna Bandi
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2018-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Diffuse large B-cell lymphoma
non-Hodgkin's lymphoma
rituximab
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=316;epage=320;aulast=Advani
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=316;epage=320;aulast=Advani

Similar Items